IMDX (Insight Molecular Diagnostics) Operating Cash Flow per Share : $-1.40 (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Insight Molecular Diagnostics Operating Cash Flow per Share?

Insight Molecular Diagnostics's operating cash flow per share for the three months ended in Mar. 2025 was $-0.23. Insight Molecular Diagnostics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.40.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 41.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 26.40% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Insight Molecular Diagnostics's Operating Cash Flow per Share or its related term are showing as below:

IMDX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -37.4 Med: -9.5 Max: 41.9
Current: 41.9

During the past 12 years, Insight Molecular Diagnostics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 41.90% per year. The lowest was -37.40% per year. And the median was -9.50% per year.

IMDX's 3-Year OCF Growth Rate is ranked better than
84.12% of 170 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.8 vs IMDX: 41.90

Insight Molecular Diagnostics Operating Cash Flow per Share Historical Data

The historical data trend for Insight Molecular Diagnostics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insight Molecular Diagnostics Operating Cash Flow per Share Chart

Insight Molecular Diagnostics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-7.94

-8.08

-8.23

-3.05

-1.59

Insight Molecular Diagnostics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.46	-0.46	-0.41	-0.31	-0.23

Competitive Comparison of Insight Molecular Diagnostics's Operating Cash Flow per Share

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insight Molecular Diagnostics's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Insight Molecular Diagnostics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Insight Molecular Diagnostics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-20.713	/	13.071
	=	-1.58

Insight Molecular Diagnostics's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-5.858	/	25.694
	=	-0.23

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40

Insight Molecular Diagnostics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Insight Molecular Diagnostics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Insight Molecular Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Insight Molecular Diagnostics Inc (NAS:IMDX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

0KCC:UK

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.

Executives

Broadwood Partners Lp	10 percent owner	BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno	director	C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs	officer: Interim CEO	15 CUSHING, IRVINE CA 92618
John Peter Gutfreund	other: Former Director	767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley	director	150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Lou Silverman	director
James Yang Liu	officer: Controller, PAO	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last	director	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter	director	C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith	director	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John	officer: SVP, Finance, and Interim CFO	C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011